Key result
Dobutamine provides effective cardiac support with fewer life-threatening side effects than current inotropes.
Why the study?
Does dobutamine reduce side effects compared to currently used inotropic drugs in patients with pump failure?
Does dobutamine reduce side effects compared to currently used inotropic drugs in patients with pump failure?
Dobutamine is introduced as a new inotropic agent for pump failure with potentially fewer life-threatening side effects than existing options.
Should not yet alter inotropic choices for pump failure; leaves open randomized trials to confirm dobutamine's reduced side effects.
When pump failure threatens to stop your patient's heart, inotropic drugs may help pull him through. There's just one problem: The side effects of inotropics currently used may cause the patient a whole new set of troubles. But now along has come dobutamine (Dobutrex), a new inotropic agent that promises to do its job with a minimum of life-threatening side effects.
No takes yet. Share an insight, caveat, or question.
Angela Smith-Collins (1980) studied this question. Dobutamine (Dobutrex) is a new inotropic agent for pump failure that promises to provide effective cardiac support with fewer life-threatening side effects than currently used drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: